FindTrial
Sign In

Use of sedating antidepressant to reduce the benzodiazepine use in patients with depression

Open Label, Randomized Control Trial of use Mirtazapine in reduction of chronic Benzodiazepine use in patients with Major Depressive disorder: study at outpatient department of tertiary care hospital.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/08/044959
Enrollment
60
Registered
2022-08-26
Start date
Unknown
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F325- Major depressive disorder, singleepisode, in full remission

Interventions

Intervention1: Mirtazapine tablet 7.5 mg: The approved dose for major depressive disorder is upto 45mg. the dose to be used for this study is 7.5mg Control Intervention1: Diazepam tablet 5mg: Equivale

Sponsors

Drashti Manishbhai Shah
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients known case of MDD in remission for 3 months or more 2. Currently no history of alcohol use in last 3 months

Exclusion criteria

Exclusion criteria: Patients with other disorders than MDD

Design outcomes

Primary

MeasureTime frame
To stop benzodiazepines in patients with major depressive disorderTimepoint: 3 months—

Secondary

MeasureTime frame
to decrease medication burden in patients with major depressive disorderTimepoint: 3 months—

Countries

India

Contacts

Public ContactDrashti Manishbhai Shah

GMERS Medical College and Hospital, Gotri, Vadodara

hod.psy.gotri@gmail.com9824060682

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026